A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3.
Study details:
Primary objectives. This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts - an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives:. Part A To assess the safety and efficacy of lanifibranor compared to placebo on 'NASH resolution and improvement of fibrosis' assessed by liver histology.
Part B To assess the safety of lanifibranor beyond the DBPC period. Secondary objectives. Key secondary objectives of Part 1:.
* To assess the effect of lanifibranor compared to placebo on NASH resolution and no worsening of fibrosis. * To assess the effect of lanifibranor compared to placebo on improvement of fibrosis with no worsening of NASH. Other secondary objectives of both Part 1 and Part 2:.
* To assess the effect of lanifibranor on other key histological features of NASH (only for DBPC period). * To assess the effect of lanifibranor on NASH resolution and improvement of fibrosis in diabetic patients (only for DBPC period). * To assess the effect of lanifibranor on liver tests.
* To assess the effect of lanifibranor on glycaemic parameters. * To assess the effect of lanifibranor on lipid parameters. * To assess the effect of lanifibranor on liver stiffness and steatosis assessed by elastography.
* To assess the effect of lanifibranor on health-related quality of life. * To assess the safety of lanifibranor. * To assess population PK modeling through plasma levels of lanifibranor using sparse sampling scheme (only for DBPC period).
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
- Male or female, aged ≥18 years at the time of signing informed consent
- Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF): Steatosis score ≥1, Activity score: A3 or A4, Fibrosis score: F2 or F3
- No qualitative change in dose for the drugs listed below: Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months, Vitamin E (if at a dose ≥400 IU/day): for at least 6 months, Statins: for at least 3 months
- No qualitative change in dose for all other chronically administered drugs for at least 3 months prior to Screening
- Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)
- Negative serum pregnancy test at study Screening for females of childbearing potential confirmed by central laboratory. Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 1 month after treatment discontinuation.
Exclusion criteria
- Documented causes of chronic liver disease other than NASH
- Histologically documented liver cirrhosis (fibrosis stage F4)
- History or current diagnosis of hepatocellular carcinoma (HCC)
- History of or planned liver transplant
- Positive human immunodeficiency virus (HIV) serology
- ALT or AST >5 × ULN
- AST<0.6 ULN if the liver biopsy has to be performed in the scope of the study
- Abnormal synthetic liver function as defined by Screening central laboratory evaluation
- Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males
- Patient currently receiving any approved treatment for NASH or obesity
- Current or recent history (<5 years) of significant alcohol consumption
- Treatment with drugs that may cause non-alcoholic fatty liver disease (NAFLD) administered for at least 2 weeks within 12 months prior to qualifying liver biopsy
- HbA1c >9% at Screening
- Diabetes mellitus other than type 2
- Current treatment with insulin
- Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy.
- Bariatric surgery: Restrictive procedures are allowed, if performed >6 months prior to the qualifying liver biopsy; malabsorptive procedures and procedures combining both restrictive and malabsorptive methods are not allowed within 5 years of the qualifying liver biopsy.
- History of heart failure with reduced left ventricular ejection fraction (LVEF)
- Atrial fibrillation requiring anticoagulation
- Unstable heart failure
- Uncontrolled hypertension at Screening (values >160/100 mm Hg)
- Women currently breastfeeding
- Previous exposure to lanifibranor
- Participation in any clinical trial investigational medicinal product/device within 3 months from Screening or 5 half-lives from Screening, whichever is longer
- Concomitant treatment with PPAR-alpha agonists (fibrates)
Eligibility
Age eligible for study : NA
Healthy volunteers accepted : No
Gender eligible for study: ALL
Things to know
Study dates
Study start:
Primary completion:
Study completion finish:
Study type
TREATMENT
Phase
- PHASE3
Study ID
NCT04849728
Intervention or treatment
DRUG: IVA337
DRUG: Placebo
Conditions
- NASH - Nonalcoholic Steatohepatitis
You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.
Research sites nearby
Closest Location:
Concord Repatriation General Hospital
Select from list below to view details:
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Campbelltown Hospital
Liverpool, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
John Hunter Hospital
New Lambton, New South Wales, Australia
Loading map...
Who is running the clinical trial?
Inventiva Pharma
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: Lanifibranor (IVA 337) (800 mg/day)
| Drug: IVA337, Drug: Placebo |
EXPERIMENTAL: Lanifibranor (IVA 337) (1200 mg/day)
| Drug: IVA337 |
PLACEBO_COMPARATOR: Matching placebo
| Drug: Placebo |
What is the study measuring?
Primary Outcome
| Measure | Description | Time Frame |
|---|---|---|
| Resolution of NASH and improvement of fibrosis | Part A: DBPC: Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline | Part A: Date of randomisation until the date of biopsy at Week 72 |
| Safety Analyses | Part B: ATE: * Using the DBPC on-treatment period, comparing the 2 active arms versus placebo * Using the DBPC +ATE on treatment periods, assessing the 2 active arms. For adverse events, adjudicated liver events, and DILI and MACE events, in addition to the raw cumulative incidence proportions, the exposure-adjusted incidence rates will be provided based on the time patients are at risk. | 48 weeks after completion of DBPC period |
Secondary Outcome
References
Clinical Trials Gov: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Other trials to consider
Loading suggested trials...
